ArticleBioMed research international2025
New Gene Signature-Based Prognostic Model for Patients With VEGF-Overexpressing Esophageal Squamous Cell Carcinoma.
Article in BioMed research international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New Gene Signature-Based Prognostic Model for Patients With VEGF-Overexpressing Esophageal Squamous Cell Carcinoma.BioMed research international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The effects of vascular endothelial growth factor (VEGF) overexpression on the prognosis of patients with esophageal squamous cell carcinoma (ESCC) are still unclear. The aim of this study was to construct and evaluate a mutant gene-based model to predict the prognosis of ESCC patients with VEGF overexpression. Methods: Samples from 50 ESCC patients with VEGF overexpression were subjected to next-generation sequencing (NGS) to identify gene mutations. The associations between the enrichment of these mutations and patient outcomes were also evaluated in a cohort from The Cancer Genome Atlas. Hazard ratios were identified via the Kaplan-Meier and Cox analyses. A support vector machine recursive feature elimination algorithm was used to construct the model, and receiver operating characteristic analysis was carried out to evaluate its prognostic performance. Results: ESCC patients with Conclusion: A model based on a four-gene signature effectively predicts the prognosis of ESCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.